Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: The impact of varying the discount rate for health

被引：12

作者：

de Vries, Robin ^{[1
]}

Klok, Rogier M. ^{[1
]}

Brouwers, Jacobus R. B. J. ^{[2
]}

Postma, Maarten J. ^{[1
]}

机构：

[1] Univ Groningen, Dept Pharm, Unit Pharmacoepidemiol & Pharmacoecon, Groningen, Netherlands

[2] Univ Groningen, Dept Pharm, Unit Pharmacotherapy & Pharmaceut Care, Groningen, Netherlands

来源：

VACCINE | 2009年 / 27卷 / 06期

关键词：

Helicobacter pylori; Cost-effectiveness; Discount rate; ECONOMIC-EVALUATION; GASTRIC-CANCER; INFECTION; PREVENTION;

D O I：

10.1016/j.vaccine.2008.11.081

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To estimate the cost-effectiveness of a potential Helicobacter pylori (HP) vaccine for the Dutch situation, we developed a Markov model. Several HP prevalence scenarios were assessed. Additionally, we assessed the impact of the discount rate for health on the outcomes, as this influence can be profound for vaccines. When applying the current discount rate of 1.5% for health, the expected cost-effectiveness of HP vaccination is estimated below the informal Dutch threshold of (sic)20,000/LYG when the HP prevalence is assumed >= 20% in the Dutch population. In conclusion, we showed that HP vaccination could possibly be a cost-effective intervention. However, this depends to a large extend on the prevalence of HP in the population. Furthermore, we showed the large impact of the discount rate for health on the cost-effectiveness of a HP vaccination program, illustrative for other vaccination programs. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：846 / 852

页数：7

共 44 条

[1]

[Anonymous], Statistics Netherlands

[2]

[Anonymous], 1994, INFECT HELICOBACTER, V61, P177

[3]

Bos Jasper M, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P247, DOI 10.1586/14737167.4.3.247

[4] Discounting health effects in pharmacoeconomic evaluations: Current controversies [J].

Bos, JM ;

Postma, MJ ;

Annemans, L .

PHARMACOECONOMICS, 2005, 23 (07) :639-649

[5] Valuing prevention through economic evaluation - Some considerations regarding the choice of discount model for health effects with focus on infectious diseases [J].

Bos, JM ;

Beutels, P ;

Annemans, L ;

Postma, MJ .

PHARMACOECONOMICS, 2004, 22 (18) :1171-1179

[6] An introduction to Markov modelling for economic evaluation [J].

Briggs, A ;

Sculpher, M .

PHARMACOECONOMICS, 1998, 13 (04) :397-409

[7] Handling uncertainty in cost-effectiveness models [J].

Briggs, AH .

PHARMACOECONOMICS, 2000, 17 (05) :479-500

[8] Need for differential discounting of costs and health effects in cost effectiveness analyses [J].

Brouwer, WBF ;

Niessen, LW ;

Postma, MJ ;

Rutten, FFH .

BRITISH MEDICAL JOURNAL, 2005, 331 (7514) :446-448

[9]

Danesh J, 1999, ALIMENT PHARM THERAP, V13, P851

[10] Migrant communities constitute a possible target population for primary prevention of Helicobacter pylori-related complications in low incidence countries [J].

De Vries, Annemarie C. ;

Van Driel, Harold F. ;

Richardus, Jan H. ;

Ouwendijk, Martine ;

Van Vuuren, Adriana J. ;

De Man, Rob A. ;

Kuipers, Ernst J. .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2008, 43 (04) :403-409

← 1 2 3 4 5 →